Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions

Use of adoptive T-cell therapy modified with chimeric antigen receptor (CAR-T) has revolutionized treatment of patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). CAR-T cells directed against CD19 antigen have produced response rates as high as 90% in clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenbaum, Uri, Mahadeo, Kris Michael, Kebriaei, Partow, Shpall, Elizabeth J., Saini, Neeraj Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480185/
https://www.ncbi.nlm.nih.gov/pubmed/32984022
http://dx.doi.org/10.3389/fonc.2020.01594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480185/
https://www.ncbi.nlm.nih.gov/pubmed/32984022
http://dx.doi.org/10.3389/fonc.2020.01594

Ejemplares similares